Načítá se...
An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis
BACKGROUND AND PURPOSE: Butyrate has shown benefits in inflammatory bowel diseases. However, it is not often administered orally because of its rancid smell and unpleasant taste. The efficacy of a more palatable butyrate‐releasing derivative, N‐(1‐carbamoyl‐2‐phenylethyl) butyramide (FBA), was evalu...
Uloženo v:
| Vydáno v: | Br J Pharmacol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5429328/ https://ncbi.nlm.nih.gov/pubmed/27684049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13637 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|